Maia Wealth LLC Buys Shares of 14,602 Biomea Fusion, Inc. (NASDAQ:BMEA)

Maia Wealth LLC bought a new stake in shares of Biomea Fusion, Inc. (NASDAQ:BMEA) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 14,602 shares of the company’s stock, valued at approximately $62,000.

Other hedge funds have also made changes to their positions in the company. Barclays PLC raised its holdings in shares of Biomea Fusion by 156.3% during the third quarter. Barclays PLC now owns 39,620 shares of the company’s stock valued at $401,000 after acquiring an additional 24,162 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Biomea Fusion by 0.7% in the third quarter. Geode Capital Management LLC now owns 601,479 shares of the company’s stock valued at $6,076,000 after purchasing an additional 4,291 shares during the last quarter. SG Americas Securities LLC acquired a new stake in shares of Biomea Fusion in the fourth quarter valued at approximately $58,000. FMR LLC increased its holdings in shares of Biomea Fusion by 0.7% in the third quarter. FMR LLC now owns 5,431,525 shares of the company’s stock valued at $54,858,000 after purchasing an additional 39,959 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of Biomea Fusion by 3.8% in the third quarter. Charles Schwab Investment Management Inc. now owns 208,391 shares of the company’s stock valued at $2,105,000 after purchasing an additional 7,551 shares during the last quarter. Institutional investors and hedge funds own 96.72% of the company’s stock.

Analyst Upgrades and Downgrades

BMEA has been the subject of several recent research reports. D. Boral Capital reaffirmed a “buy” rating and issued a $128.00 price target on shares of Biomea Fusion in a report on Friday, January 10th. HC Wainwright reaffirmed a “buy” rating and issued a $40.00 price target on shares of Biomea Fusion in a report on Tuesday, January 14th. Two equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, Biomea Fusion presently has an average rating of “Buy” and an average target price of $39.36.

Biomea Fusion Stock Performance

Shares of Biomea Fusion stock opened at $2.64 on Tuesday. The firm has a market capitalization of $95.67 million, a price-to-earnings ratio of -0.66 and a beta of -0.34. Biomea Fusion, Inc. has a fifty-two week low of $2.58 and a fifty-two week high of $18.50. The stock has a 50 day moving average of $3.84 and a 200 day moving average of $6.60.

About Biomea Fusion

Biomea Fusion, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes.